查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594981

報導基因分析的全球市場

Reporter Gene Assays
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 88 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球報導基因分析市場將達到 99 億美元

報導基因分析的全球市場預計 2023 年為 63 億美元，預計到 2030 年將達到 99 億美元，在 2023-2030 年分析期間複合年成長率為 6.7%。螢光素酶檢測是本報告分析的細分市場之一，複合年成長率為 7.6%，預計到分析期結束時將達到 41 億美元。在分析期間，螢光蛋白相關檢測領域的複合年成長率預計為 7.0%。

美國市場預計19億美元，中國預計複合年成長率6.2%

預計 2023 年美國報導基因分析市場規模將達 19 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達17億美元，2023-2030年分析期間複合年成長率為6.2%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 6.1% 和 5.4%。在歐洲，德國預計複合年成長率為 5.0%。

全球報導基因分析市場—主要趨勢和促進因素總結

報導基因分析在現代研究中扮演什麼角色？

報導基因分析在生物醫學研究、遺傳學和藥物開發領域至關重要，是監測基因表現和細胞事件的重要工具。在這些測定中，產生易於測量的蛋白質的「報告」基因被插入目標細胞中。當目標基因或啟動子被活化時，報導基因也會表達其蛋白質，從而實現基因活性的可視化和量化。該技術為研究人員提供了關於細胞路徑、基因表現動態和各種疾病機制的寶貴見解。對報導基因分析的需求正在顯著成長，因為它們提供了一種可靠、高效和非侵入性的觀察細胞行為的方法，使科學家能夠更好地即時了解細胞反應。鑑於分子生物學和遺傳學研究的激增，報導基因分析正在成為研究的重要組成部分，特別是在癌症生物學、神經生物學和免疫學等應用中。

此外，報導基因分析在藥物發現中也很重要，用於評估潛在化合物的功效和毒性。製藥公司嚴重依賴這些檢測方法，透過監測候選藥物與特定細胞路徑的相互作用來識別有前途的候選藥物。例如，報告基因檢測可以測量特定受體的激活，例如 G 蛋白偶聯受體 (GPCR)。報導基因分析可在細胞層面上即時洞察藥物活性，使研究人員能夠在開發過程的早期識別副作用，從而節省時間和資源。這樣，報導基因分析就發揮了促進基礎研究和加強藥物發現管道的雙重作用，使其成為各個科學領域的寶貴工具。

科技進步如何影響報導基因分析？

技術進步顯著提高了報導基因分析的效率、靈敏度和適用性。例如，生物發光和螢光成像等成像技術的創新使得報導基因活性的可視化變得更加精確。生物發光檢測與基因表現表現結合發光，由於其高靈敏度和低背景噪音而越來越受歡迎，可以更準確地測量基因表現。同樣，綠色螢光蛋白（GFP）等螢光報導基因由於能夠產生可在顯微鏡下觀察到的生動視覺輸出而被廣泛採用。成像技術的這些進步徹底改變了報導基因分析的基因表現。

此外，高通量篩檢技術的發展使研究人員能夠利用報導基因分析進行大規模研究，特別是在藥物發現方面。高通量系統能夠快速測試數千種化合物，並有效評估它們對特定基因和途徑的影響。自動化系統和資料分析使研究人員能夠快速識別潛在的候選藥物並加速藥物發現過程。此外，CRISPR-Cas9技術與報導基因分析的結合進一步擴大了其應用範圍。基於 CRISPR 的編輯可以精確操作特定基因，而報告基因分析可以讓研究人員直接觀察這些基因修飾的效果。隨著技術的進步，報導基因分析將變得更加通用、適應性更強，並且對生命科學研究和開發至關重要。

報導基因分析面臨哪些挑戰和機會？

儘管報導基因分析在研究中發揮重要作用，但它也存在一定的限制和挑戰。一項主要挑戰是來自細胞成分的潛在干擾或“背景噪音”，這有時會影響測定結果的準確性。內源性細胞因子，例如天然存在的酵素和蛋白質，可以與報告基因反應，產生假陽性或陰性結果，從而掩蓋真實結果。這個問題在涉及複雜細胞類型或多基因相互作用的測定中尤其嚴重，因為細胞異質性會使訊號解釋變得複雜。另一個挑戰是需要專門的設備和技術專業知識來進行和解釋研究，這需要資源，並對小型實驗室和研究機構構成障礙。

然而，這些挑戰正在為報導基因分析市場的創新創造機會。例如，對具有更高特異性和靈敏度的檢測的需求不斷成長，這推動了新型報導基因和最佳化檢測格式的開發。分裂螢光素酶和分裂 GFP 系統等創新旨在透過分離僅在發生特定細胞間相互作用時發出訊號的報告蛋白來減少背景雜訊並提高測定精度。此外，隨著越來越多的製藥公司和學術研究機構認知到報導基因分析的價值，提供專業檢測服務的委外研發機構(CRO) 的市場也在不斷擴大。這些 CRO 提供進行報導基因分析的專業知識和設備，使研究機構能夠克服技術和財務限制。透過採用創新解決方案來應對這些挑戰，報導基因分析市場有望持續發展和發展，以滿足現代科學研究的需求。

加速報導基因分析市場的關鍵促進因素是什麼？

報導基因分析市場的成長是由反映科學研究和生物技術進步的幾個因素所推動的。癌症、神經退化性疾病和感染疾病等疾病的日益流行，推動了對精確分子工具的需求，以幫助闡明疾病機制。報導基因分析為研究疾病途徑和製定治療策略提供了一種有價值的方法，特別是在腫瘤學和免疫學領域，了解基因調控對於有效治療至關重要。此外，基因研究的增加和 CRISPR 基因編輯技術的採用正在加速需求。研究人員經常使用報導基因分析來評估特定基因修飾對細胞功能的影響。能夠即時觀察 CRISPR 編輯引起的基因表現變化的報告基因檢測對於此類前沿研究至關重要。

另一個關鍵促進因素是製藥公司和學術研究機構對藥物發現研發的投資增加。隨著製藥業加大對標靶治療和精準醫療的投資，對報導基因分析等可靠、高效的檢測方法的需求正在迅速增加。高通量篩檢能力使報告基因檢測更具可擴展性，使研究人員能夠快速篩檢大型化合物庫。此外，在研究中擴大使用 3D 細胞培養和類器官模型，增加了對報導基因分析的需求，這些檢測可以在複雜的生物系統中有效地發揮作用，並產生更多的生理相關結果。最後，政府對生命科學研究的支持政策和資助，特別是在美國和歐洲，正在進一步提振市場。這些促進因素共同推動了報導基因分析市場的發展，並確保其在生物醫學和藥物研究中的持續重要性。

部分

類型（螢光素酶測定、螢光蛋白相關測定、氯黴素乙醯轉移酶測定、BETA-半乳糖苷酶測定、BETA-葡萄醣醛酸酶測定、其他類型）、應用（臨床、體外研究）、最終用途（製藥/生技）公司、CRO、學術/研究機構、醫院/診斷實驗室）

調查企業舉例（共32家）

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biotium
  • Danaher Corporation
  • Genecopoeia, Inc.
  • Geno Technology, Inc.
  • Invivogen
  • Merck KGaA
  • Perkinelmer
  • Promega Corporation
  • Promocell
  • Thermo Fisher Scientific, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP22700

Global Reporter Gene Assays Market to Reach US$9.9 Billion by 2030

The global market for Reporter Gene Assays estimated at US$6.3 Billion in the year 2023, is expected to reach US$9.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Luciferase Assays, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Fluorescent Protein-Related Assays segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 6.2% CAGR

The Reporter Gene Assays market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Reporter Gene Assay Market - Key Trends & Drivers Summarized

What Role Do Reporter Gene Assays Play in Modern Research?

Reporter gene assays are pivotal in the fields of biomedical research, genetics, and drug development, serving as essential tools for monitoring gene expression and cellular events. In these assays, a "reporter" gene, which produces an easily measurable protein, is inserted into a target cell. When the target gene or promoter is activated, the reporter gene also expresses its protein, making it possible to visualize or quantify gene activity. This technique provides researchers with valuable insights into cellular pathways, gene expression dynamics, and the mechanisms of various diseases. The demand for reporter gene assays has grown significantly as they provide a reliable, efficient, and non-invasive means to observe cellular behavior, allowing scientists to better understand cellular responses in real time. Given the surge in molecular biology and genetic research, reporter gene assays are becoming an indispensable component of research, particularly in applications such as cancer biology, neurobiology, and immunology.

Moreover, reporter gene assays are critical in drug discovery, where they are used to evaluate the efficacy and toxicity of potential drug compounds. Pharmaceutical companies rely heavily on these assays to identify promising drug candidates by monitoring their interactions with specific cellular pathways. For instance, reporter assays can measure the activation of certain receptors, such as G-protein coupled receptors (GPCRs), which are often targeted in drug development. By providing real-time insights into drug activity at a cellular level, reporter gene assays enable researchers to identify adverse effects early in the development process, saving time and resources. This dual role of reporter gene assays—advancing fundamental research and enhancing drug discovery pipelines—has positioned them as an invaluable tool across a range of scientific disciplines.

How Are Technological Advancements Shaping Reporter Gene Assays?

Technological advancements are significantly enhancing the efficiency, sensitivity, and applicability of reporter gene assays. For example, innovations in imaging techniques, such as bioluminescence and fluorescence imaging, have enabled more precise visualization of reporter gene activity. Bioluminescent assays, which produce light upon gene expression, have gained popularity for their high sensitivity and low background noise, allowing for more accurate measurements of gene expression. Similarly, fluorescent reporter genes, such as green fluorescent protein (GFP), have been widely adopted due to their ability to produce vivid visual outputs that can be observed under a microscope. These advancements in imaging technology have transformed how researchers utilize reporter gene assays, enabling them to detect and quantify gene expression more effectively and in real time.

Additionally, developments in high-throughput screening technology have allowed researchers to conduct large-scale studies using reporter gene assays, particularly in drug discovery. High-throughput systems enable rapid testing of thousands of compounds, making it possible to assess their effects on specific genes or pathways efficiently. With automated systems and data analytics, researchers can quickly identify potential drug candidates, accelerating the discovery process. Moreover, the integration of CRISPR-Cas9 technology with reporter gene assays has further expanded their applications. CRISPR-based editing allows for precise manipulation of specific genes, and by using reporter assays, researchers can directly observe the effects of these genetic modifications. As technology advances, reporter gene assays are likely to become even more versatile, adaptable, and integral to research and development in life sciences.

What Challenges and Opportunities Lie Ahead for Reporter Gene Assays?

Despite their critical role in research, reporter gene assays face certain limitations and challenges. One major challenge is the potential for interference or “background noise” from cellular components, which can sometimes affect the accuracy of assay results. Endogenous cellular factors, such as naturally occurring enzymes or proteins, may react with the reporter, creating false positives or negatives that obscure the true results. This problem is particularly pronounced in assays involving complex cell types or multi-gene interactions, as cellular heterogeneity can complicate signal interpretation. Another challenge is the need for specialized equipment and technical expertise to conduct and interpret reporter gene assays, which can be resource-intensive and may pose a barrier for smaller research labs or institutions.

However, these challenges also bring opportunities for innovation within the reporter gene assay market. For instance, there is growing demand for assays with higher specificity and sensitivity, which has driven the development of novel reporter genes and optimized assay formats. Innovations such as split-luciferase and split-GFP systems aim to reduce background noise and increase assay accuracy by separating reporter proteins that only emit a signal when specific cellular interactions occur. Additionally, as more pharmaceutical companies and academic research institutions recognize the value of reporter gene assays, the market for contract research organizations (CROs) offering specialized assay services is expanding. These CROs provide expertise and equipment for conducting reporter gene assays, allowing institutions to overcome technical and financial limitations. By addressing these challenges with innovative solutions, the reporter gene assay market is poised to grow and evolve, meeting the needs of modern scientific research.

What Are the Key Drivers Accelerating the Reporter Gene Assay Market?

The growth in the reporter gene assay market is driven by several factors that reflect advancements in scientific research and biotechnology. The increasing prevalence of diseases such as cancer, neurodegenerative disorders, and infectious diseases has fueled the demand for precise molecular tools that can help decode disease mechanisms. Reporter gene assays provide an invaluable method for studying disease pathways and developing therapeutic strategies, particularly in oncology and immunology, where understanding gene regulation is crucial for effective treatment. Furthermore, the rise in genetic research and the adoption of CRISPR gene editing technology have accelerated demand, as researchers frequently use reporter gene assays to assess the impact of specific genetic modifications on cellular functions. The ability to observe real-time changes in gene expression due to CRISPR edits has made reporter assays indispensable in these advanced studies.

Another key driver is the expanding investment in drug discovery and development by both pharmaceutical companies and academic research institutions. As the pharmaceutical industry invests more in targeted therapies and precision medicine, the demand for reliable and efficient testing methods like reporter gene assays has surged. High-throughput screening capabilities have made reporter assays more scalable, allowing researchers to screen large compound libraries quickly. Additionally, the increased use of 3D cell cultures and organoid models in research has led to a growing need for reporter gene assays that can work effectively in complex biological systems, enabling more physiologically relevant results. Finally, supportive government policies and funding for life sciences research, particularly in the United States and Europe, have further boosted the market. Together, these drivers are propelling the reporter gene assay market forward, ensuring its ongoing importance in biomedical and pharmaceutical research.

SCOPE OF STUDY:

The report analyzes the Reporter Gene Assays market in terms of US$ Million by the following Application; End-Use; Type, and Geographic Regions/Countries:

Segments:

Type (Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays, Other Types); Application (Clinical, In-Vitro Studies); End-Use (Pharma & Biotech Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biotium
  • Danaher Corporation
  • Genecopoeia, Inc.
  • Geno Technology, Inc.
  • Invivogen
  • Merck KGaA
  • Perkinelmer
  • Promega Corporation
  • Promocell
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Reporter Gene Assays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for High-throughput Screening Drives Adoption of Advanced Reporter Gene Assay Technologies
    • Growing Emphasis on Precision Medicine Strengthens Demand for Reporter Gene Assays in Drug Development
    • Rise in Gene Therapy Research Expands Addressable Market for Reporter Gene Assay Applications
    • Advancements in CRISPR and Gene Editing Technologies Propel Growth of Reporter Gene Assays for Target Validation
    • Increasing Focus on Cancer Research Spurs Demand for Reporter Gene Assays in Oncology Studies
    • Expansion of Cell-based Assays for Drug Discovery Drives Adoption of Reporter Gene Assay Tools
    • Growing Integration of Reporter Gene Assays in High-content Screening Expands Opportunities in Complex Studies
    • Technological Innovations in Bioluminescent and Fluorescent Reporters Enhance Sensitivity and Market Demand
    • Adoption of 3D Cell Culture Systems and Organoids Drives Demand for Compatible Reporter Gene Assay Solutions
    • Increasing Need for Real-time Gene Expression Monitoring in Research Boosts Market for Dynamic Reporter Assays
    • Rising Investments in Biotechnology and Pharmaceutical R&D Spur Growth in the Reporter Gene Assay Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Reporter Gene Assays Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Reporter Gene Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Reporter Gene Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Luciferase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Luciferase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Fluorescent Protein-Related Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Fluorescent Protein-Related Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chloramphenicol Acetyltransferase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Chloramphenicol Acetyltransferase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Beta-Galactosidase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Beta-Galactosidase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Beta-Glucuronidase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Beta-Glucuronidase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for In-Vitro Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for In-Vitro Studies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • JAPAN
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • CHINA
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • EUROPE
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for Reporter Gene Assays by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Europe 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • FRANCE
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: France 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • GERMANY
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Germany 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Italy 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • UNITED KINGDOM
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: UK 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: Rest of World 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030

IV. COMPETITION